Profound Medical Corp. (PROF)

Intra-Cellular Therapies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	46.43	54.91	26.21	46.52	67.15	83.91
Cash & Short-Term Investments	46.43	54.91	26.21	46.52	67.15	83.91
Cash Growth	12.76%	109.48%	-43.65%	-30.73%	-19.97%	466.98%
Accounts Receivable	5.29	6.43	6.75	5.84	1.41	6.45
Other Receivables	0.67	0.62	0.53	0.51	-	0.99
Receivables	5.97	7.05	7.29	6.34	1.41	7.43
Inventory	6.8	5.8	6.99	7.94	7.41	5.33
Prepaid Expenses	0.72	1.31	1.41	1.22	1.15	1.07
Total Current Assets	59.91	69.07	41.9	62.02	77.13	97.74
Property, Plant & Equipment	0.65	0.82	1.57	1.72	1.9	2.28
Goodwill	-	-	-	-	2.69	2.68
Other Intangible Assets	0.21	0.26	0.49	0.68	1.44	1.9
Long-Term Accounts Receivable	-	-	-	-	3.62	-
Long-Term Deferred Tax Assets	0.09	0.09	-	-	-	-
Total Assets	60.86	70.23	43.96	64.42	86.78	104.6
Accounts Payable	1.05	1.32	0.87	2.03	3.18	3.38
Accrued Expenses	3.35	2.84	2.42	-	-	-
Current Portion of Long-Term Debt	-	1.74	2.1	0.52	-	-
Current Portion of Leases	0.26	0.26	0.26	0.24	0.25	0.31
Current Income Taxes Payable	-	-	-	0.3	-	0.01
Current Unearned Revenue	0.64	0.42	0.72	0.47	0.48	0.36
Other Current Liabilities	-	-	-	0.62	0.25	0.74
Total Current Liabilities	5.3	6.57	6.37	4.18	4.16	4.81
Long-Term Debt	4.49	2.92	5	6.65	-	-
Long-Term Leases	0.14	0.2	0.5	0.82	1.13	1.36
Long-Term Unearned Revenue	0.09	0.05	0.73	0.76	0.88	1.08
Long-Term Deferred Tax Liabilities	-	-	0.06	-	-	-
Other Long-Term Liabilities	0.07	0.07	0.07	-	-	-
Total Liabilities	10.07	9.81	12.73	12.42	6.16	7.25
Common Stock	281.64	281.55	222.21	205.83	219.58	211.53
Additional Paid-In Capital	22.2	21.3	20.81	18.7	16.99	11.25
Retained Earnings	-255.89	-245.17	-217.35	-189.36	-160.69	-129.99
Comprehensive Income & Other	2.85	2.74	5.57	16.84	4.75	4.57
Shareholders' Equity	50.79	60.42	31.22	52	80.62	97.35
Total Liabilities & Equity	60.86	70.23	43.96	64.42	86.78	104.6
Total Debt	4.88	5.12	7.87	8.23	1.38	1.68
Net Cash (Debt)	41.55	49.79	18.35	38.29	65.78	82.24
Net Cash Growth	22.15%	171.40%	-52.08%	-41.79%	-20.02%	2047.74%
Net Cash Per Share	1.59	2.01	0.87	1.84	3.21	4.76
Filing Date Shares Outstanding	30.05	30.04	24.43	20.91	20.78	20.29
Total Common Shares Outstanding	30.05	30.04	21.37	20.88	20.78	20.21
Working Capital	54.62	62.5	35.53	57.84	72.97	92.93
Book Value Per Share	1.69	2.01	1.46	2.49	3.88	4.82
Tangible Book Value	50.58	60.16	30.73	51.32	76.49	92.77
Tangible Book Value Per Share	1.68	2.00	1.44	2.46	3.68	4.59
Machinery	1.71	2.27	2.58	0.54	1.2	1.83
Leasehold Improvements	0.54	0.54	0.54	1.84	0.58	0.55

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q